{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012519","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.087709+00:00","generated_at":"2026-05-31T07:06:31.043747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phibro Q4 net sales up 7% to $273.2M; FY2025 guidance sees 10% adjusted EBITDA growth","bullets":["Q4 GAAP net income of $0.8M ($0.02 EPS) vs $11.5M ($0.28 EPS) YoY; adjusted EPS $0.41 (+10%).","Full-year net sales $1,017.7M (+4%); adjusted EBITDA $111.2M (-1%); adjusted EPS $1.19 (-1%).","FY2025 guidance: net sales $1.04B-$1.09B, adjusted EBITDA $118M-$126M, adjusted EPS $1.22-$1.37.","Free cash flow $46.4M; total debt $489.1M; cash & short-term investments $114.6M; gross leverage 4.4x.","Guidance excludes proposed Zoetis MFA acquisition; company notes strength in Q4 Animal Health segment."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012519","json":"https://secwatch.observer/filing/0001558370-24-012519.json","markdown":"https://secwatch.observer/filing/0001558370-24-012519.md","text":"https://secwatch.observer/filing/0001558370-24-012519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024012519/0001558370-24-012519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024012519/pahc-20240828x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:06:31.043747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}